Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical lab tests

This article was originally published in The Gray Sheet

Executive Summary

Final rule establishing national Medicare coverage policies for 23 clinical diagnostic laboratory tests, including prothrombin time and fecal occult blood tests, is published Nov. 23 in the Federal Register. The rule incorporates six changes to a March 2000 proposed rule, including removing "egregious overutilization" as an exception Medicare contractors may use to pursue frequency-based denial of claims, and removing a provision in the "reasons for denial" section limiting coverage of non-FDA-approved devices to category B IDEs. CMS notes that it will be modifying regulations on IDEs following the creation of a clinical trials coverage policy in September 2000. In addition, the effective date for provisions requiring computer system adjustments is changed to Nov. 25, 2002. All other provisions are effective Feb. 21, 2002...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT015732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel